Nevertheless, in contrast to previous observations, the availability of more cumulative data from retrospective analyses revealed that MMR status can not be used to predict response to fluoropyrimidine therapy in stage II colon cancer [33]. The gene discussed is MRC1; the disease is malignant colon neoplasm.